Camargo Pharmaceutical Services Release: CEOs Say 505(b)(2) Pathway Will Drive Growth In Generic Industry
2/27/2014 9:52:44 AM
CINCINNATI--(BUSINESS WIRE)--To better understand where the generic market is heading, a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts at this year’s Generic Pharmaceutical Association (GPhA) annual meeting. This year, Ronny Gal, Ph.D., senior analyst with Sanford C. Bernstein, and Randall Stanicky, managing director for equity research with RBC Capital Markets, met with the CEOs of Mylan, Hospira, Teva, Apotex and Momenta.
Help employers find you! Check out all the jobs and post your resume.
comments powered by